Twitter Facebook LinkedIn YouTube

Monarch Energy (CSE: CHX) New Listing

Video Platform Video Management Video Solutions Video Player

Concurrent with its new CSE listing, the company has voluntarily de-listed from the TSX Venture Exchange Monarch has disposed of its mineral and oil and gas properties and has completed the acquisition of ChroMedX Ltd.

Additional Information:

Company: Monarch Energy
Website: http://www.chromedx.com/
Stock Symbol: CSE: CHX
Date Published: Jul 7, 2014
Transcript: Available

Video Transcript:

I’m Renee Hammond for Investmentpitch Media

Monarch Energy is one of the latest new listings on the Canadian Securities Exchange, and is trading under the symbol “CHX”.

Concurrent with its new CSE listing, the company has voluntarily de-listed from the TSX Venture Exchange Monarch has disposed of its mineral and oil and gas properties and has completed the acquisition of ChroMedX Ltd.

The company plans to change its name at the next annual and special meeting of the shareholders.

ChroMedX will have two platform technologies.

The initial platform will focus on devices and methodologies for blood sample collection and analysis.

The company’s technology provides for rapid analysis of hemoglobin status and blood oxygenation as well as acid/base balance, which is an essential tool for patient evaluation.

This information is of particular importance for first responder patient evaluation and in emergency and operating rooms in healthcare facilities.

The second technology platform is based on ultrafiltration and will be applied to several applications.

The first will provide plasma separation from whole blood during blood collection which avoids the step of centrifugation in the laboratory.

The second application will process plasma to remove proteins in preparation for analysis.

Proof of concept for this technology has been demonstrated.

ChroMedX intends to develop its technologies in collaboration with major hospitals and universities and will seek strategic relationships with existing medical diagnostic companies, as well as companies that desire to enter into the field of medical diagnostics.

The company will be seeking investment of $1-2 million for initial prototype manufacture and testing as well as business development.

The total world market for In Vitro Diagnostics is estimated to reach $58.6 billion in 2014, with Point of Care Testing representing approximately 29% of this market or $16.9 billion.

Monarch is trading at $0.10 and with 29.8 million shares outstanding the company is capitalized at $3 million.

For more information, please contact Wayne Maddever at 647-872-9982 or Clark Kent, Corporate Development at 647-519-2646 or by email at ckent@chromedx.com.


I’m Renee Hammond for Investmentpitch Media
For more video news, and to view our disclaimer, please visit our website at www.investmentpitch.com
This video is for information purposes only and it not a recommendation to buy or sell any securities.